Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Novel vaccine strategy to enhance mucosal immune responses against HIV-1 and STIs in the female genital tract
FY 2017-18
Summary
Human immunodeficiency virus (HIV) is a major global health issue, with 36 million individuals infected worldwide and over 1.5 million deaths occurring due to infection each year. With no cure currently available, an HIV vaccine is urgently needed. This is especially troubling for women, who are at higher risk for infection with HIV and other sexually transmitted infections (STIs) compared to men. The aim of this research project is to develop a vaccination strategy for HIV that will generate better protection in the female genital tract (FGT), the primary site of infection during heterosexual transmission. We believe we can achieve this by using estradiol, a female sex hormone which has shown to be protective against susceptibility to STIs. Based on previous studies done with herpes infection, another viral STI, we predict that estradiol will increase tissue-resident memory T cells, a newly described subset of cells, and improve antibody responses against HIV. Tissue-resident memory T cells are generated following immunization, and are programmed to remain within the FGT. As a result, these cells are readily available to help control infection and provide rapid protection. To test our vaccination strategy, we will immunize mice using a novel HIV candidate vaccine, and examine the immune response generated to determine the effect of estradiol treatment. We will also characterize these novel memory T cells in human endometrium and cervix tissues from pre- and post-menopausal women, to determine how hormone levels can influence these cell populations. The knowledge generated from this project will fundamentally improve women's reproductive health by: 1) offering an efficacious vaccination strategy for STIs, and 2) emphasizing the need to keep sex-specific immune responses in consideration during vaccine development.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
383283
Name
Bagri Puja
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Novel vaccine strategy to enhance mucosal immune responses against HIV-1 and STIs in the female genital tract
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Female Reproductive Tract; Female Sex Hormones; Hiv-1; Immunity; Infection; Sexually Transmitted Infections; Vaccine; Women'S Reproductive Health
Abstract
Human immunodeficiency virus (HIV) is a major global health issue, with 36 million individuals infected worldwide and over 1.5 million deaths occurring due to infection each year. With no cure currently available, an HIV vaccine is urgently needed. This is especially troubling for women, who are at higher risk for infection with HIV and other sexually transmitted infections (STIs) compared to men. The aim of this research project is to develop a vaccination strategy for HIV that will generate better protection in the female genital tract (FGT), the primary site of infection during heterosexual transmission. We believe we can achieve this by using estradiol, a female sex hormone which has shown to be protective against susceptibility to STIs. Based on previous studies done with herpes infection, another viral STI, we predict that estradiol will increase tissue-resident memory T cells, a newly described subset of cells, and improve antibody responses against HIV. Tissue-resident memory T cells are generated following immunization, and are programmed to remain within the FGT. As a result, these cells are readily available to help control infection and provide rapid protection. To test our vaccination strategy, we will immunize mice using a novel HIV candidate vaccine, and examine the immune response generated to determine the effect of estradiol treatment. We will also characterize these novel memory T cells in human endometrium and cervix tissues from pre- and post-menopausal women, to determine how hormone levels can influence these cell populations. The knowledge generated from this project will fundamentally improve women's reproductive health by: 1) offering an efficacious vaccination strategy for STIs, and 2) emphasizing the need to keep sex-specific immune responses in consideration during vaccine development.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bagri, Puja
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~